Phase 3 N=478 Mylan Insulin Aspart Study
Diabetes Mellitus, Type 1
Primary: Treatment Emergent Antibody Response (TEAR) — 59; 67 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=204 Study of Efficacy and Safety of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis Patients With Active Enthesitis Including One Achilles Tendon Site
Psoriatic Arthritis · Axial Spondyloarthritis · Enthesitis
Primary: Number (%) of Patients With Resolution of Achilles Tendon Enthesitis — 43; 32 Participants — p=0.136
Phase 3 N=853 Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
Psoriatic Arthritis
Primary: Percentage of Participants Who Achieved an American College of Rheumatology 20% (ACR20) Response at Week 52 — 67.4; 61.5 Percentage of Participants — p=0.0719
Phase 3 N=147 Comparison of Three Different Pain Blocks for Subjects Undergoing VATS (Video Assisted Thoracoscopic Surgery) Procedure.
Video Assisted Thoracoscopic Surgery · Pain, Postoperative · Pain, Acute
Primary: The Primary Endpoint of This Study Will be VAS Pain Score at 24 Hours — 4.0; 4.5; 3.0 units on a scale
Phase 3 N=1,113 Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment
COVID-19
Primary: Part A: Percentage of Participants in Each Clinical Status Category as Assessed by a 7-Point Ordinal Scale on Day 11 — 0.0; 1.0; 2.0; 0.0 percentage of participants…
Phase 3 N=82 Management of Etonogestrel Subdermal Implant-related Bleeding
ESI-related Bleeding
Primary: Secondary Treatment — 20; 23 Participants — p=0.37
Phase 3 N=13 Belatacept Therapy for the Failing Renal Allograft
Failing Renal Allograft
Primary: Number of Participants With Donor-specific Antibody Formation — 3; 4 Participants
Phase 3 N=825 Phase III Study of Liquid Formulation of ROTAVIN
Diarrhea · Diarrhea Rotavirus
Primary: Geometric Mean Concentration (GMC) of Serum Anti-rotavirus Immunoglobulin A (IgA) Antibodies 28 Days After Second Vaccination — 48.25; 35.04 U/mL
Phase 3 N=1,103 Topical Vancomycin for Neurosurgery Wound Prophylaxis
Infection · Surgery · Nervous System Diseases
Primary: Any Surgical-site Infection as Evidenced by Surgeon or Attending Physician Diagnosis, or Signs and Symptoms of Infection Assessed by Phone Call Interview or at In-office…
Phase 3 N=440 A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
Primary: Percentage of Participants Achieving Eczema Area and Severity Index 75 (EASI75) (2 mg Baricitinib) — 8.2; 29.5 percentage of participants — p=<0.001
Phase 3 N=251 Comparison Trial of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis
Atopic Dermatitis
Primary: Responder Rate of Investigator's Global Assesment (IGA) of Disease Severity — 44.58; 47.06; 18.07 percentage of participants
Phase 3 N=364 Comparison Trial of OPA-15406 Ointment in Adult Patients With Atopic DermatitisSyndrome
Atopic Dermatitis
Primary: Responder Rate of Investigator's Global Assesment(IGA) of Disease Severity — 38.46; 12.64 percentage of perticipants
Phase 3 N=471 A Study Comparing LY900014 to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes Using Insulin Pump Therapy
Type 1 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 16 — -0.09; -0.06 Percentage of HbA1c — p=0.565
Phase 3 N=126 Comparing Efficacy and Safety of Stivant (AryoGen Bevacizumab) Versus Avastin in Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Primary: Progression Free Survival (PFS) — 232; 210 Day — p=0.47
Phase 3 N=469 To Compare Safety and Efficacy of Perrigo's Drug Compared to an FDA Approved Drug in the Treatment of Actinic Keratosis
Actinic Keratosis
Primary: Number of Participants With Complete Clearance (Absence) of Actinic Keratosis Lesions — 71; 71; 9 Participants